Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather H Cheng

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
The Prostate|September 20, 2017
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Heather H Cheng, Wassim Abida, et al.
European Urology|June 18, 2024
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD TrialRuben Raychaudhuri, Makayla DeJong, Matthew Rettig, et al.
Urologic Oncology|February 17, 2019
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancerAndrew W Hahn, David D Stenehjem, Anitha B Alex, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
Prostate Cancer and Prostatic Diseases|January 3, 2024
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics boardStacy Loeb, Heather H Cheng, Channing J Paller, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Complexities of Next-Generation Sequencing in Solid Tumors: Case StudiesAlexandra O Sokolova, Brian H Shirts, Eric Q Konnick, et al.
Plos One|June 14, 2013
Plasma processing conditions substantially influence circulating microRNA biomarker levelsHeather H Cheng, Hye Son Yi, Yeonju Kim, et al.
The Prostate|June 22, 2016
A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic CounselingHeather H Cheng, Nola Klemfuss, Bruce Montgomery, et al.
The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.
Prostate Cancer and Prostatic Diseases|February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancerRisa L Wong, Mai T Duong, Catherine M Tangen, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
The Prostate|September 20, 2017
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Heather H Cheng, Wassim Abida, et al.
European Urology|June 18, 2024
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD TrialRuben Raychaudhuri, Makayla DeJong, Matthew Rettig, et al.
Urologic Oncology|February 17, 2019
Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancerAndrew W Hahn, David D Stenehjem, Anitha B Alex, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
Prostate Cancer and Prostatic Diseases|January 3, 2024
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics boardStacy Loeb, Heather H Cheng, Channing J Paller, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
Complexities of Next-Generation Sequencing in Solid Tumors: Case StudiesAlexandra O Sokolova, Brian H Shirts, Eric Q Konnick, et al.
Plos One|June 14, 2013
Plasma processing conditions substantially influence circulating microRNA biomarker levelsHeather H Cheng, Hye Son Yi, Yeonju Kim, et al.
The Prostate|June 22, 2016
A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic CounselingHeather H Cheng, Nola Klemfuss, Bruce Montgomery, et al.
The Prostate|November 7, 2017
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancerHeather H Cheng, Melissa Plets, Hongli Li, et al.
Prostate Cancer and Prostatic Diseases|February 15, 2020
Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancerRisa L Wong, Mai T Duong, Catherine M Tangen, et al.
Pageof 15